<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="article-commentary" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OURD</journal-id>
<journal-title>Our Dermatol Online</journal-title>
<issn pub-type="epub">2081-9390</issn>
<publisher>
<publisher-name>Our Dermatology Online</publisher-name>
<publisher-loc>Poland</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">OURD-6-375</article-id>
<article-id pub-id-type="doi">10.7241/ourd.20153.102</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Comment to the Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A case of pityriasis rosea of vidal accompanied by neurofibromatosis type 1</article-title>
<subtitle>The association of <italic>pityriasis circin&#x00E9; et margin&#x00E9;</italic> and neurofibromatosis type 1</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chuh</surname>
<given-names>Antonio</given-names>
<suffix>Ass. Prof.</suffix>
</name>
<degrees>MD FRCP FRCPCH</degrees>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zawar</surname>
<given-names>Vijay</given-names>
<suffix>Prof.</suffix>
</name>
<degrees>MD DNB DV&#x0026;D FAAD</degrees>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<author-comment>
<p>by Ahu Yorulmaz, Ferda Artuz, Sezer Kulacoglu, Elif Sen</p>
</author-comment>
</contrib-group>
<aff id="aff1"><label>1</label><italic>School of Public Health, The Chinese University of Hong Kong and Prince of Wales Hospital, Shatin, Hong Kong</italic></aff>
<aff id="aff2"><label>2</label><italic>Department of Dermatology, Godavari Foundation Medical College and Research Center, DUPMCJ, India</italic></aff>
<pub-date pub-type="ppub">
<year>2015</year>
</pub-date>
<volume>6</volume>
<issue>3</issue>
<fpage>375</fpage>
<lpage>377</lpage>
<history>
<date date-type="received"><day>17</day><month>06</month><year>2015</year></date>
<date date-type="accepted"><day>18</day><month>06</month><year>2015</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x000a9; Our Dermatol Online 3</copyright-statement>
<copyright-year>2015</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
</permissions>
<related-article xmlns:xlink="http://www.w3.org/1999/xlink" id="RAI" journal-id-type="OURD" page="372" vol="6" issue="1" related-article-type="commentary-article"><article-title>A case of pityriasis rosea of vidal accompanied by neurofibromatosis type 1</article-title></related-article>
</article-meta>
</front>
<body>
<sec id="sec1-1">
<title>COMMENTS</title>
<p>We read with pleasure the case report by Yorulmaz A <italic>et al</italic> on the occurrence of <italic>pityriasis circin&#x00E9; et margin&#x00E9;</italic> which is a variant of pityriasis rosea (PR) in a 23-year-old lady with known neurofibromatosis type 1 (NF-1) [<xref ref-type="bibr" rid="ref1">1</xref>].</p>
<p>We agree to both diagnoses [<xref ref-type="bibr" rid="ref2">2</xref>-<xref ref-type="bibr" rid="ref4">4</xref>]. Both diseases are uncommon, but definitely not rare. We have no data on the prevalence of NF-1 in Turkey. In the United Kingdom, the prevalence is around 1:4560 [<xref ref-type="bibr" rid="ref5">5</xref>], with the prevalence at birth being 1:2699 [<xref ref-type="bibr" rid="ref5">5</xref>]. The prevalences of NF-1 for six-year-old German children, and 9-11 year-old children in Cuba, are 1:2996 [<xref ref-type="bibr" rid="ref6">6</xref>] and 1:1141 [<xref ref-type="bibr" rid="ref7">7</xref>] respectively. The prevalence of PR is around 1:167 [<xref ref-type="bibr" rid="ref8">8</xref>]. This means that if a clinic follows 200 patients with NF-1, and sees them once every year, around 1.20 patient with PR would be expected to be seen.</p>
<p>While reporting them concomitantly in one individual, we might consider exploring the mechanisms as to whether these two diseases: (1) are merely co-incidental; (2) are being innocent bystanders (NF-1); (3) are related to the same confounder(s), and (4) have underlying immunopathogenetic connections, which could be risk factors, precipitating factors, or be genuine causal relationships.</p>
<p>For patient with NF-1, the immunological system is compromised to various extents [<xref ref-type="bibr" rid="ref9">9</xref>-<xref ref-type="bibr" rid="ref12">12</xref>]. The processes are not comprehensively known, although it is likely that multiple immunological pathways and cellular mechanisms reduce the antigen-processing and antigen-presenting cells in NF-1 [<xref ref-type="bibr" rid="ref12">12</xref>].</p>
<p>Moreover, large groups of immune function genes in human Schwann cells are down-regulated in NF-1 [<xref ref-type="bibr" rid="ref13">13</xref>]. Acute phase reactants such as interleukins are reported to be adversely affected in NF-1 [<xref ref-type="bibr" rid="ref13">13</xref>]. Other than systematic effects, topical immunological responses could also be compromised [<xref ref-type="bibr" rid="ref11">11</xref>], which might facilitate the inoculation of viruses at the herald patch, a postulation not yet substantiated.</p>
<p>A simplified immunopathological sequence would be: primary viral infection in childhood, the body then launches a primary and non-specific immunological response, then clonal expansion of T-cells (<italic>memory cells</italic>), then life-long latent infection of the virus in the peripheral blood mononuclear cells, then physical or psychological stresses together with NF-1 weakening the immunity, then endogenous reactivation of the viruses, then secondary immunological response (mainly by cell-mediated immunity), then the visible PR rash. The immunological basis for the predilected sites of lesions in bilateral axillae and groins in <italic>pityriasis circin&#x00E9; et margin&#x00E9;</italic>, however, is completely unknown.</p>
<p>For other paraviral exanthems, eruptive pseudoangiomatosis was reported to be associated with hospitalisations and treatment for cancers [<xref ref-type="bibr" rid="ref14">14</xref>]. It was postulated that relative immunocompromisation is the missing link. We have reported the association of Gianotti-Crosti syndrome &#x2013; another paraviral exanthem &#x2013; and hyperimmunoglobulinaemia E syndrome (Job&#x2019;s syndrome), which is a congenital immunodeficiency disease [<xref ref-type="bibr" rid="ref15">15</xref>]. Whether relative immunocompromisation is associated with other paraviral exanthems, such as asymmetric periflexural exanthem (unilateral laterothoracic exanthem) and papular-purpuric gloves and socks syndrome, is yet to be investigated.</p>
<p>Finally, we congratulate Yorulmaz A and his colleagues for such an outstanding piece of work which can be applied to patients immediately. We humbly recommend Yorulmaz A <italic>et al</italic> and other investigators to explore the possible associations between relative immunocompromisation and PR or other paraviral exanthems.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahu</surname>
<given-names>Yorulmaz</given-names>
</name>
<name>
<surname>Ferda</surname>
<given-names>Artuz</given-names>
</name>
<name>
<surname>Kulacoglu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>A case of pityriasis rosea of vidal accompanied by neurofibromatosis type 1</article-title>
<source>Our Dermatol Online</source>
<year>2015</year>
<volume>6</volume>
<fpage>373</fpage>
<lpage>375</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Aylsworth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pyeritz</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2</article-title>
<source>JAMA</source>
<year>1997</year>
<volume>278</volume>
<fpage>51</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuh</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity</article-title>
<source>J Eur Acad Dermatol Venereol</source>
<year>2003</year>
<volume>17</volume>
<fpage>101</fpage>
<lpage>3</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zawar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Chuh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Applicability of proposed diagnostic criteria of pityriasis rosea: results of a prospective case-control study in India</article-title>
<source>Indian J Dermatol</source>
<year>2013</year>
<volume>58</volume>
<fpage>439</fpage>
<lpage>42</lpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giblin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>
<article-title>Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service</article-title>
<source>Am J Med Genet A</source>
<year>2010</year>
<volume>152A</volume>
<fpage>327</fpage>
<lpage>32</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lammert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Prevalence of neurofibromatosis 1 in German children at elementary school enrollment</article-title>
<source>Arch Dermatol</source>
<year>2005</year>
<volume>141</volume>
<fpage>71</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orraca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morej&#243;n</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Men&#233;ndez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Orraca</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis 1 prevalence in children aged 9-11 years, Pinar del R&#237;o Province, Cuba</article-title>
<source>MEDICC Rev</source>
<year>2014</year>
<volume>16</volume>
<fpage>22</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="ref8">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Traore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Korsaga-Some</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Niamba</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sanou</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Drabo</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<article-title>Pityriasis rosea in secondary schools in Ouagadougou, Burkina Faso</article-title>
<source>Ann Dermatol Venereol</source>
<year>2001</year>
<volume>128</volume>
<fpage>605</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref9">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Imafuku</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Anthropometric characteristics and comorbidities in Japanese patients with neurofibromatosis type 1: a single institutional case-control study</article-title>
<source>J Dermatol</source>
<year>2014</year>
<volume>41</volume>
<fpage>885</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref10">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerosa</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Bizzozero</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Spinelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vai</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Immune reaction in von Recklinghausen&#x2019;s neurofibromatosis</article-title>
<source>Minerva Med</source>
<year>1991</year>
<volume>82</volume>
<fpage>613</fpage>
<lpage>25</lpage>
</nlm-citation>
</ref>
<ref id="ref11">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerosa</surname>
<given-names>PL1</given-names>
</name>
<name>
<surname>Vai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bizzozero</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Local immune response in neurofibromatosis type 1 and type 2</article-title>
<source>Minerva Med</source>
<year>1993</year>
<volume>84</volume>
<fpage>23</fpage>
<lpage>31</lpage>
</nlm-citation>
</ref>
<ref id="ref12">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Immune system evasion by peripheral nerve sheath tumour</article-title>
<source>Neurosci Lett</source>
<year>2006</year>
<volume>397</volume>
<fpage>126</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref13">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luangwedchakarn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jirapongsaranuruk</surname>
<given-names>O</given-names>
</name>
<name>
<surname>NiemeLa</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Thepthai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chokephaibulkit</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sukpanichnant</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>A novel mutation of the IL12RB1 gene in a child with nocardiosis, recurrent salmonellosis and neurofibromatosis type I: first case report from Thailand</article-title>
<source>Asian Pac J Allergy Immunol</source>
<year>2009</year>
<volume>27</volume>
<fpage>161</fpage>
<lpage>5</lpage>
</nlm-citation>
</ref>
<ref id="ref14">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillot</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dandurand</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Eruptive pseudoangiomatosis arising in adulthood: 9 cases</article-title>
<source>Eur J Dermatol</source>
<year>2000</year>
<volume>10</volume>
<fpage>455</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref15">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The association of hyperimmunoglobulin E syndrome and Gianotti-Crosti syndrome &#x2013; speculations on the roles of atopy and immunoglobulin E in a viral exanthem</article-title>
<source>Pediatr Infect Dis J</source>
<year>2005</year>
<volume>24</volume>
<fpage>942</fpage>
</nlm-citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="supported-by">
<p><bold>Source of Support:</bold> Nil,</p>
</fn>
<fn fn-type="conflict">
<p><bold>Conflict of Interest:</bold> None declared.</p>
</fn>
</fn-group>
</back>
</article>
